Table 2. Efficacy of atezolizumab compared to docetaxel according to PD-L1 expression.

PD-L1 expression level	% of patients	Hazard ratio for OS	P value	Hazard ratio for PFS
Intent to treat	100	0.73	0.0003	0.95
IC O and TC 0	42	0.75	0.0215	NR
IC 1/2/3 or TC 1/2/3	57	0.74	0.0102	NR
IC 2/3 or TC 2/3	30	0.67	0.0080	NR
IC 3 or TC 3	17	0.41	<0.0001	0.63

OS, overall survival; PFS, progression-free survival; NR, not reported.